PE01462009A1 - immunogenic composition against influenza virus - Google Patents

immunogenic composition against influenza virus

Info

Publication number
PE01462009A1
PE01462009A1 PE2008000650A PE0006502008A PE01462009A1 PE 01462009 A1 PE01462009 A1 PE 01462009A1 PE 2008000650 A PE2008000650 A PE 2008000650A PE 0006502008 A PE0006502008 A PE 0006502008A PE 01462009 A1 PE01462009 A1 PE 01462009A1
Authority
PE
Peru
Prior art keywords
per dose
tlr
5mg
amount
influenza virus
Prior art date
Application number
PE2008000650A
Other languages
Spanish (es)
Inventor
William Ripley Ballou
Emmanuel Jules Hanon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB0707697A priority Critical patent/GB0707697D0/en
Priority to GB0711357A priority patent/GB0711357D0/en
Priority to GB0712062A priority patent/GB0712062D0/en
Priority to PCT/EP2007/060743 priority patent/WO2008043774A1/en
Priority to GB0724651A priority patent/GB0724651D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE01462009A1 publication Critical patent/PE01462009A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/409Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Leishmania i.e. Leishmaniasis, Sand-fly fever, phlebotomus fever, kala-azar, black fever or Dumdum fever
    • Y02A50/41Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Leishmania i.e. Leishmaniasis, Sand-fly fever, phlebotomus fever, kala-azar, black fever or Dumdum fever the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera

Abstract

SE REFIERE A COMPOSICIONES INMUNOGENICAS CONTRA LA GRIPE, QUE COMPRENDEN: A)UN ANTIGENO DEL VIRUS INFLUENZA QUE CONSISTE EN 15ug O MENOS DE HA POR DOSIS; It REFERS TO FLU immunogenic compositions comprising: a) an antigen INFLUENZA VIRUS CONSISTING 15ug OR LESS THAN HA per dose; B)UN COADYUVANTE DE EMULSION DE ACEITE EN AGUA, COMPUESTO POR: a)UN ACEITE METABOLIZABLE, TAL COMO ESCUALENO EN 0,5-10mg A 9-10mg POR DOSIS; B) A adjuvant oil-in-water, comprising: a) a metabolizable OIL AS A squalene in 0,5-10mg 9-10mg per dose; b)UN AGENTE EMULSIVO, TAL COMO MONOOLEATO DE POLIOXIETILENSORBITANO, TRIOLEATO DE SORBITANO O MEZCLA DE AMBOS EN CANTIDAD DE 0,1-5mg A 4-5mg POR DOSIS; b) an emulsifying agent such as polyoxyethylenesorbitan monooleate, sorbitan trioleate or mixtures thereof in an amount of 0,1-5mg A 4-5mg per dose; c)UN TOCOL, EN CANTIDAD DE 0,5-12 A 10-11mg POR DOSIS; c) a tocol in an amount of 0.5-12 A 10-11mg per dose; UN ESTEROL EN CANTIDAD DE 0,025-2,5mg A 0,125-0,25mg POR DOSIS; A sterol 0,025-2,5mg AMOUNT OF A 0,125-0,25mg per dose; O AMBOS; Or both; d)UN LIGANDO TLR, TAL COMO TLR-1, TLR-2, TLR-3, ENTRE OTROS, O COMBINACIONES DE LOS MISMOS; d) TLR ligand, AS TLR-1, TLR-2, TLR-3, among others, or combinations thereof; e)UNA SAPONINA, TAL COMO QS21 EN 5-60ug A 40-50ug POR DOSIS. e) a saponin, QS21 AS IN 5-60ug A 40-50ug per dose. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. ALSO it REFERS TO A preparation process. DICHA COMPOSICION PUEDE SER MONO O MULTIVALENTE DE VIRUS COMPLETO, DIVIDIDO O VIROSOMA DE UNO O MAS ANTIGENOS PURIFICADOS ELEGIDOS DE: HA, NA, M1, M2; Such composition may be mono- or multivalent whole virus, or virosome DIVIDED one or more antigens PURIFIED CHOSEN: HA, NA, M1, M2; COMPRENDIENDO ANTIGENOS SELECCIONADOS DE LAS CEPAS: H1N1, H3N2, B/yamagata, B/victoria, H5N1, ENTRE OTRAS, Y SE ADMINISTRA EN DOSIS MENORES A 1,2mL UNDERSTANDING SELECTED STRAINS Antigens: H1N1, H3N2, B / yamagata, B / Victoria, H5N1, among others, and is administered in doses less than 1.2ml
PE2008000650A 2006-10-12 2008-04-15 immunogenic composition against influenza virus PE01462009A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB0707697A GB0707697D0 (en) 2007-04-20 2007-04-20 Vaccine
GB0711357A GB0711357D0 (en) 2007-06-12 2007-06-12 Vaccine
GB0712062A GB0712062D0 (en) 2007-06-21 2007-06-21 Vaccine
PCT/EP2007/060743 WO2008043774A1 (en) 2006-10-12 2007-10-10 Vaccine comprising an oil in water emulsion adjuvant
GB0724651A GB0724651D0 (en) 2007-12-18 2007-12-18 Vaccine

Publications (1)

Publication Number Publication Date
PE01462009A1 true PE01462009A1 (en) 2009-03-23

Family

ID=39766893

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000650A PE01462009A1 (en) 2006-10-12 2008-04-15 immunogenic composition against influenza virus

Country Status (21)

Country Link
US (4) US9452209B2 (en)
EP (2) EP2455101A3 (en)
JP (1) JP2010524883A (en)
KR (1) KR101188382B1 (en)
CN (2) CN105311629A (en)
AR (1) AR066405A1 (en)
AT (1) AT537841T (en)
AU (1) AU2008240761B2 (en)
BR (1) BRPI0810015A2 (en)
CA (1) CA2683075C (en)
CO (1) CO6251369A2 (en)
CR (1) CR11122A (en)
DO (1) DOP2009000239A (en)
EA (1) EA024250B1 (en)
ES (1) ES2377761T3 (en)
IL (1) IL200859A (en)
MA (1) MA31381B1 (en)
PE (1) PE01462009A1 (en)
TW (1) TW200908994A (en)
WO (1) WO2008128939A1 (en)
ZA (1) ZA200906753B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2228454T3 (en) * 1999-02-26 2005-04-16 Chiron S.R.L. Improved bacterial activity of Neisseria antigens with oligonucleotides containing cg reasons.
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
DE10144906B4 (en) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Process for the large-scale production of vaccines
CA2601022A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
CA2664619C (en) * 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
AR066405A1 (en) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vaccine
AU2008281384C1 (en) 2007-08-02 2012-08-16 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2009155489A2 (en) 2008-06-19 2009-12-23 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
CN102307590A (en) * 2009-02-10 2012-01-04 诺华有限公司 Influenza vaccines with reduced amounts of squalene
SI2396030T1 (en) * 2009-02-10 2015-12-31 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
JP2012525370A (en) 2009-04-27 2012-10-22 ノバルティス アーゲー Adjuvanted vaccine to protect against influenza
KR20120117008A (en) * 2009-10-21 2012-10-23 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 폭스겐트존하이트 벨지인 엔 스포츠 Methods for diagnosis of immune responses against viruses
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
CN102802662A (en) 2010-03-18 2012-11-28 诺华有限公司 Adjuvanted vaccines for serogroup B meningococcus
WO2011130652A2 (en) * 2010-04-15 2011-10-20 George Baer Compositions and methods for vaccinating humans and animals against enveloped viruses
CA2801149A1 (en) * 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
US10286056B2 (en) * 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
CN103517713A (en) * 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
JP2014532620A (en) * 2011-10-20 2014-12-08 ノバルティス アーゲー Adjuvant-added influenza B virus vaccine for primary immunization in children
CN104159608A (en) * 2012-03-06 2014-11-19 克鲁塞尔荷兰公司 Improved vaccination against influenza
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
JPWO2016104584A1 (en) * 2014-12-25 2017-10-05 第一三共株式会社 Intradermally administered influenza vaccine composition

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DD155875A1 (en) 1980-12-31 1982-07-14 Willy Nordheim Method for producing a balance-free inactivated influenza vaccine
US4454119A (en) 1981-06-29 1984-06-12 Mitsubishi Chemical Industries Limited Therapeutic agents
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
FI69639C (en) 1982-07-02 1986-03-10 Orion Yhtymae Oy Prepare Foer anvaendning at Chlamydia diagnostik
DD211444A3 (en) 1982-08-19 1984-07-11 Saechsisches Serumwerk Process for the production of influenza vaccines
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
FI861417A0 (en) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis B ytantigen framstaelld with a recombinant DNA technician, vaccinia, test kit agents, and cellinjer samt foerfaranden Foer framstaellning daerav.
DD300833A7 (en) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Method for the production of inactivated influenza full virus vaccines
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JP2851288B2 (en) 1987-06-05 1999-01-27 アメリカ合衆国 Autocrine motility factor in cancer diagnosis and management
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
DE3734306A1 (en) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Discharge for fliessfaehige media
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
AT115862T (en) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocols as a vaccine adjuvant.
JPH0832638B2 (en) 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising a submicron oil emulsion
EP0414374B1 (en) 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
DE4005528C2 (en) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Discharge for Media
US5969109A (en) 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
US5149531A (en) 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
KR100251505B1 (en) 1991-11-16 2000-05-01 장 스테판느 Hybrid protein between cs from plasmodium and hbsag
MA22842A1 (en) 1992-03-27 1993-10-01 Smithkline Beecham Biolog vaccine compositions of Preparation Method.
AU6141094A (en) 1993-02-19 1994-09-14 Smithkline Beecham Biologicals (Sa) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE69428136T3 (en) 1993-03-23 2008-07-10 Smithkline Beecham Biologicals S.A. 3-0 Deazylierte monophosphoryl lipid A containing vaccine compositions
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
PL181241B1 (en) 1993-11-17 2001-06-29 Laboratoires Om S.A. Glucosoamine disaccharides, method of obtaining them and pharmaceutical composition containing them as well as their application
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995022989A1 (en) 1994-02-24 1995-08-31 Micro-Pak, Inc. Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
PT772619E (en) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
US5629052A (en) 1995-02-15 1997-05-13 The Procter & Gamble Company Method of applying a curable resin to a substrate for use in papermaking
EP0812358A1 (en) 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
BR9608199B1 (en) 1995-04-25 2009-05-05 vaccine composition comprising an antigen, QS21 and a sterol.
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US20030133944A1 (en) 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6130043A (en) 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L A device for controlling the depth 'of penetration of a needle, in particular applicable to a syringe for injections
CN101219217A (en) 1998-05-07 2008-07-16 科里克萨有限公司 Adjuvant composition and methods for its use
HU0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
ES2284275T3 (en) 1998-06-30 2007-11-01 Om Pharma Acylated pseudodipeptides new, their preparation procedures and pharmaceutical compositions including them.
AT408615B (en) 1998-09-15 2002-01-25 Immuno Ag New influenza virus vaccine composition
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AT407958B (en) 1999-02-11 2001-07-25 Immuno Ag Inactivated influenza virus vaccine for nasal or oral application
EP2286792A1 (en) 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Microemulsions with an adsorbent surface, comprising a microdroplet emulsion
IL150756D0 (en) 2000-01-31 2003-02-12 Smithkline Beecham Biolog Novel use of hiv proteins
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1201250A1 (en) 2000-10-25 2002-05-02 Institut Pasteur Immunogenic compositions comprising liver stage malarial antigens
DE60239594D1 (en) 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vaccine compositions for intradermal administration
CA2444130C (en) 2001-04-17 2010-12-21 Sumitomo Pharmaceuticals Company, Limited Adenine derivatives
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
JP2005513021A (en) 2001-11-16 2005-05-12 スリーエム イノベイティブ プロパティズ カンパニー Irm compounds and methods and compositions relating toll-like receptor pathway
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
US20040074760A1 (en) * 2002-10-17 2004-04-22 Carnegie Mellon University Production of biofuels
AT426412T (en) 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvant influenza vaccine-
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
CN1522691A (en) * 2003-09-05 2004-08-25 韦怀新 Nucleic acid, protein polypeptide and vaccine emulsion preparation method
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
CA2601022A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
AR054822A1 (en) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion immuno adjuvant
JP2009514850A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Influenza vaccine with a reduced amount of oil-in-water emulsion as an adjuvant
EP2368572A3 (en) 2005-11-04 2013-04-24 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2664619C (en) 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
FR2896162B1 (en) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion oil in water thermo
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
DK2043682T3 (en) * 2006-07-17 2014-06-02 Glaxosmithkline Biolog Sa Influenza vaccine
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
AR066405A1 (en) * 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vaccine
JP2011506290A (en) 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Influenza composition
US8362284B2 (en) * 2009-04-21 2013-01-29 Dow Technology Investments Llc Method of achieving and maintaining a specified alkylene oxide production parameter with a high efficiency catalyst

Also Published As

Publication number Publication date
US20100189741A1 (en) 2010-07-29
EP2136837A1 (en) 2009-12-30
CR11122A (en) 2010-03-22
TW200908994A (en) 2009-03-01
CA2683075C (en) 2015-11-10
IL200859D0 (en) 2010-05-17
US9597389B2 (en) 2017-03-21
US10016495B2 (en) 2018-07-10
KR20100009576A (en) 2010-01-27
CN101678096A (en) 2010-03-24
EA200901161A1 (en) 2010-06-30
MA31381B1 (en) 2010-05-03
EP2455101A3 (en) 2013-04-24
BRPI0810015A2 (en) 2014-10-14
US20180339037A1 (en) 2018-11-29
AT537841T (en) 2012-01-15
CA2683075A1 (en) 2008-10-30
CN105311629A (en) 2016-02-10
US20170246290A1 (en) 2017-08-31
AU2008240761B2 (en) 2014-05-29
ZA200906753B (en) 2010-12-29
EP2455101A2 (en) 2012-05-23
AR066405A1 (en) 2009-08-19
US9452209B2 (en) 2016-09-27
IL200859A (en) 2015-10-29
KR101188382B1 (en) 2012-10-08
ES2377761T3 (en) 2012-03-30
DOP2009000239A (en) 2009-11-15
WO2008128939A1 (en) 2008-10-30
EP2136837B1 (en) 2011-12-21
US20090136543A1 (en) 2009-05-28
JP2010524883A (en) 2010-07-22
EA024250B1 (en) 2016-08-31
CO6251369A2 (en) 2011-02-21
AU2008240761A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
CL2012003226A1 (en) Compounds derived from 5-fluoro-1H-pyrazolopyridine; preparation process thereof; framaceutica composition it comprising; and their use in the treatment of cardiovascular, sexual and metabolic diseases.
AR071074A1 (en) Particle supply
BRPI0619133A2 (en) Chimeric influenza viruses, recombinant DNA molecule, the method for producing an immunogenic formulation chimeric NDV, and method for inducing an immune response to infectious agents both
GT201500312A (en) Sulfamoilpirrolamida derivatives and their use as medicaments for the treatment of hepatitis b
BRPI0616672A2 (en) compound, pharmaceutical composition, use of a compound, and process for preparing a compound
UY34993A (en) Sulfamoilarilamidas and their use as medicaments for the treatment of hepatitis b
AR063892A1 (en) Delivery particles containing beneficial agents
DOP2014000008A (en) 4-imidazopyridazine-1-yl-benzamide and 4-imidazotriazine-1-yl-benzamides as inhibitors btk
CL2013001982A1 (en) Method to reduce glucose levels and treat metabolic disorders thereof; pharmaceutical composition comprising metformin and another antidiabetic agent or anti-obesity.
CL2014000370A1 (en) Alafenamida hemifumarate tenofovir; Preparation method; pharmaceutical composition comprising the same; method for preparing the pharmaceutical composition; and use in the treatment of HIV infection.
CO6481009A2 (en) cosmetic preparation for hair and médtodo for the application thereof
CR20120090A (en) highly concentrated pharmaceutical formulations
GT201200147A (en) Spiro-oxindole antagonists of mdm2
CO6290791A2 (en) Immunogenic compositions and vaccines containing virus new strains of porcine type 2b circus immunizing swine against PMWS for
ECSP088175A (en) sustained release of anti-infective agents
AR061333A1 (en) Vaccine compositions neisseria
CU23552A1 (en) vaccine composition
CL2010001360A1 (en) immunogenic composition comprising an antigen component and an adjuvant formulation which comprises a saponin, a sterol, a quaternary ammonium and a polymer; preparation process; and their uses.
CL2013002185A1 (en) Compounds derived modified c-17 and c3, maturation inhibitors of HIV terpenes; intermediate compounds; pharmaceutical composition comprising; its use to treat HIV infection.
ECSP10010513A (en) Compounds and compositions as modulators of activity tlr
CO5540349A2 (en) vaccinia virus preparation inactivated influenza
AR077605A1 (en) Subcutaneous formulation of anti-HER2 antibody
BRPI0707733A2 (en) Antigens, flu, vaccine compositions, and methods related
AR081515A1 (en) Agent supporting a glass-ceramic material
CR11612A (en) Recombinant virus-like particles of influenza (VLP) produced in transgenic plants expressing hemagglutinin

Legal Events

Date Code Title Description
FD Application declared void or lapsed